Cash and Cash Equivalents: As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash ...

Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million ---- December 20, 2025 PDUFA goal date ...

Direxion Daily Broadcom Bull 2X Shares offers 2x daily leveraged exposure to Broadcom, capitalizing on AI and semiconductor sector momentum. Learn more about AVL ETF here.